KRAS WT responds better to treatment compared to KRAS mutated colorectal cancers.doi:10.1016/j.ajme.2014.01.003Bader, TalhaMedical Oncology Comprehensive Cancer Centre, King Fahd Medical City, P.O. Box 59046, Riyadh 11525, Saudi Arabia;Ismail, Abdelsalam...
18. Sinicrope FA, Shi Q, Smyrk TC, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015;148(1):88-99. doi:10.1053/j.gastro.2014.09.041 19. Buscail L, Bournet B, ...
This finding was confirmed in two independent colon cancer cell lines HCT116 (KRAS mutant) and HKe3 (KRAS WT). In all three cell lines, circRNAs were also found in secreted extracellular-vesicles, and circRNAs were more abundant in exosomes than cells. Our results suggest that circRNAs may ...
Colon Colon Colon Colon Rectum Duodenum Colon Sigmoid Cecum Colon Colon Colon Cecum 1095 KRAS status c.38G4A WT WT c.35G4T c.35G4A WT WT c.34G4C, c.34G4T c.38G4A WT c.34G4T WT c.35G4A WT WT c.35G4T c.35G4T WT WT c.34G4T c.34G4T c.35G4T c.35G4A WT percentage...
Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803. Clin Cancer Res 2012; 18: 890-900.Ogino S, Shima K, Meyerhardt JA, et al: Predictive and prognostic roles of ... S Ogino,K Shima,JA Meyerhardt,... - American Associa...
Aims:KRAS mutation status is already used for tailoring therapy in colorectal cancer patients. Therefore, we investigated the relation of KRAS- and BRAF-status (mutated or wild type (WT)) with patient and tumor characteristics in the fra... P Richter-Pechanska,JB Kunz,T Rausch,... - 《Blo...
今天,我们特别关注美国康奈尔医学院陈水冰教授、Todd Evans教授团队于2023年12月26日发表在《Cell Stem Cell》(IF:23.9)的经典研究——A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS,该研究通过CRISPR/Cas9的技术构建等基因突变胰腺类器官,利用胰腺类器官进行高通量药物筛选研究,...
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive activati
It is shown here that IQc compounds 2d, 3d and 3e were able to induce cell death, mainly by apoptosis, in the wt p53 colon cancer cell line HCT116 in a dose-dependent manner and with a greater effect than 5-FU and TMPyP4 (Figure 7). In this cell line, compounds 2d, 3d and 3e...
colon, ovarian and uterus, myeloid leukemia, lymphomas, small-cell lung carcinomas (SCLC), and neuroblastoma, among others, most of which are aggressive and respond poorly to the current therapies.3,16However, unlike other common oncogenes,MYCis seldom mutated in cancer.3Nevertheless, it is ove...